Important note

This AI stock analysis for Shattuck Labs is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Shattuck Labs - AI Stock Analysis

Analysis generated January 30, 2025

Shattuck Labs is a clinical-stage biotechnology company that focuses on developing novel immunotherapy treatments for cancer and autoimmune diseases. The company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create unique, targeted therapies aimed at addressing unmet medical needs in these critical domains.

Fundamental Analysis

Shattuck Labs showed significant growth in its financial metrics during the last quarter. Revenues reached $3 million, reflecting an impressive increase of 86.26% compared to the previous quarter and a staggering 336.88% increase compared to the same quarter last year. This indicates that Shattuck Labs is on a rapid growth trajectory and successfully expanding its market reach.

The company's net income for the last quarter was $17 million, which shows a substantial growth of 22.63% from the previous quarter and 39.45% from the same quarter last year. This growth in net income is crucial as it demonstrates the company's improving profitability and operational efficiency.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) also showed robust growth, reaching $17 million, increasing by 22.88% from the previous quarter and 38.48% compared to the same quarter last year. A higher EBITDA indicates better operational performance and potential for future profitability.

Technical Analysis

Shattuck Labs’ stock is currently priced at $1.32, reflecting a short-term increase of 12.82% compared to a month ago. However, the stock price has plummeted by 86.02% over the past year, which could indicate underlying long-term risks or investor uncertainty.

The stock's trend appears to be bullish as indicated by the current 10-day Simple Moving Average (SMA10) of $1.19, which is higher than the previous SMA10 of $1.17. This suggests a potential upward trend in price movement. Meanwhile, the Relative Strength Index (RSI) is at 40, indicating a neutral condition with neither overbought nor oversold signals.

Alternative Data Analysis

Alternative data metrics provide mixed signals for Shattuck Labs. Notably, job postings have dropped to zero, indicating potential cost-cutting measures which might affect the company’s growth initiatives. However, employee sentiment remains highly positive, with 87% of employees having an optimistic outlook on the business, a good sign for internal morale and productivity.

On the customer acquisition front, website traffic has seen a worrying drop of 75% over the last couple of months, with an estimate of 1,000 visitors. This decline could indicate diminishing market interest or customer engagement, which might impact future revenue streams. Conversely, AltIndex's AI score stands at 62, signaling a buy recommendation based on a composite of fundamental, technical, and alternative data.

Conclusion

In conclusion, Shattuck Labs exhibits strong fundamental growth indicators with substantial increases in revenue, net income, and EBITDA. In the short term, the stock shows positive momentum, but the considerable long-term decline in stock price warrants caution. Alternative data points to a mixed bag of high employee morale offset by concerning dips in job postings and website traffic. Despite these challenges, the positive AI score suggests a hopeful outlook. Overall, the stock merits a cautious buy consideration, with the recommendation to closely monitor further developments in both operational performance and market reception.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.